Open AccessTreatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma
Author(s) -
Neha Korde,
Mark Roschewski,
Adriana Zingone,
Mary Kwok,
Elisabet E. Manasanch,
Manisha Bhutani,
Nishant Tageja,
Dickran Kazandjian,
Sham Mailankody,
Peter Wu,
Candis Morrison,
Rene Costello,
Yong Zhang,
Debra Burton,
Marcia Mulquin,
Diamond Zuchlinski,
Liz Lamping,
Ashley Carpenter,
Yvonne Wall,
George Carter,
Schuyler C. Cunningham,
Verena Gounden,
Tristan M. Sissung,
Cody J. Peer,
Irina Marić,
Katherine R. Calvo,
Raul C. Braylan,
Constance M. Yuan,
Maryalice StetlerStevenson,
Diane C. Arthur,
Katherine A. Kong,
Li Weng,
Malek Faham,
Liza Lindenberg,
Karen Kurdziel,
Peter L. Choyke,
Seth M. Steinberg,
William D. Figg,
Ola Landgren
Publication year - 2015
Publication title -
jama oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 8.846
H-Index - 99
eISSN - 2374-2445
pISSN - 2374-2437
DOI - 10.1001/jamaoncol.2015.2010
Subject(s) - lenalidomide , carfilzomib , medicine , multiple myeloma , dexamethasone , tolerability , adverse effect , oncology , surgery
Carfilzomib-lenalidomide-dexamethasone therapy yields deep responses in patients with newly diagnosed multiple myeloma (NDMM). It is important to gain an understanding of this combination's tolerability and impact on minimal residual disease (MRD) negativity because this end point has been associated with improved survival.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom